Safety of biologics in rheumatoid arthritis

International Journal of Clinical Rheumatology

Volumn 7, Issue 4, 2012, Pages 425-451

  Horton, Sarah C ^a,b   Nam, Jackie L ^a,b   Buch, Maya H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

abatacept; biologic; rheumatoid arthritis; rituximab; safety; TNF inhibitor; TNFi; tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; ALPHA INTERFERON; ANTIVIRUS AGENT; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LENERCEPT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NATALIZUMAB; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIBAVIRIN; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

BACTERIAL INFECTION; BRONCHOPNEUMONIA; CANCER RISK; CELLULITIS; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CROHN DISEASE; CRYOGLOBULINEMIA; DEMYELINATING DISEASE; DEMYELINATING NEUROPATHY; DIGESTIVE SYSTEM PERFORATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA VIRUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA; FIBROSIS; GUILLAIN BARRE SYNDROME; HEART FAILURE; HEMATOMA; HEPATITIS; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGLOBULIN DEFICIENCY; INFECTION RATE; INFECTION RISK; INFUSION RELATED REACTION; INJECTION PAIN; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JC VIRUS; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; LUNG DISEASE; LYMPHOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; OPTIC NEURITIS; PNEUMONIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SEPTIC SHOCK; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TUBERCULOSIS; TUBERCULOUS SPONDYLITIS; URINARY TRACT INFECTION; VASCULITIS; VIRUS LOAD; VIRUS REACTIVATION;

EID: 84865327486     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.12.37     Document Type: Review

References (177)

1. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004
2. Lipsky PE, Van Der Heijde DMFM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343(22), 1594-1602 (2000
3. van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63(5), 508-516 (2004
4. Smolen J, Landewé RB, Mease P et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68(6), 797-804 (2009
5. Fleischmann R, Vencovsky J, Van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: The FAST4WARD study. Ann. Rheum. Dis. 68(6), 805-811 (2009
6. Keystone EC, Genovese MC, Klareskog L et al. Golimumab, a human antibody to tumour necrosis factor agiven by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD study. Ann. Rheum. Dis. 68(6), 789-796 (2009
7. Emery P, Fleischmann R, Filipowicz- Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54(5), 1390-1400 (2006
8. Kremer JM, Genant HK, Moreland LW et al. effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann. Intern. Med. 144(12), 865-876 (2006
9. Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(8), 2263-2271 (2005
10. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54(9), 2817-2829 (2006
11. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 371(9617), 987-997 (2008
12. Genovese MC, Mckay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheum drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58(10), 2968-2980 (2008
13. Curtis JR, Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor aantagonists. Arthritis Rheum. 56(4), 1125-1133 (2007
14. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann. Rheum. Dis. 66(10), 1339-1344 (2007
15. Wolfe F, Caplan L, Michaud K, Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 54(2), 628-634 (2006
16. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor atherapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 56(9), 2896-2904 (2007
17. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50(1), 124-131 (2011
18. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 54(8), 2368-2376 (2006
19. Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factor-aantagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306(21), 2331-2339 (2011
20. Curtis JR, Xie F, Chen L et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann. Rheum. Dis. 70(8), 1401-1406 (2011
21. Keystone E, Heijde D, Mason D Jr et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58(11), 3319-3329 (2008
22. Singh JA, Wells GA, Christensen R et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2, CD008794 (2011
23. Smolen JS, Kay J, Doyle MK et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor ainhibitors (GO-AFTER study): A multicentre, randomised, double-blnd, placebo-controlled, Phase III trial. Lancet 374(9685), 210-221 (2009
24. Kay J, Matteson EL, Dasgupta B et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 58(4), 964-975 (2008
25. Emery P, Fleischmann RM, Moreland LW et al. Golimumab, a human anti-tumor necrosis factor a monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 60(8), 2272-2283 (2009
26. Keystone E, Genovese MC, Klareskog L et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann. Rheum. Dis. 69(6), 1129-1135 (2010
27. Kremer J, Ritchlin C, Mendelsohn A et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a Phase III randomized, double-blind, placebo controlled study. Arthritis Rheum. 62(4), 917-928 (2010
28. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-necrosis factor therapy: Results results of a multicenter, randomized, doube-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793-2806 (2006
29. Tak PP, Rigby WF, Rubbert-Roth A et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGE trial. Ann. Rheum. Dis. 70(1), 39-46 (2011
30. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials. Ann. Rheum. Dis. 68(1), 25-32 (2009
31. van Vollenhoven RF, Emery P, Bingham CO et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol. 37(3), 558-567 (2010
32. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: Data from the French registries. Rheumatology 50(1), 222-229 (2011
33. Gottenberg JE, Ravaud P, Bardin T et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 62(9), 2625-2632 (2010
34. Gottenberg JE, Ravaud P, Bardin T et al. Low serum IgG level after rituximab is associated with an increased risk of seriousctions in rheumaritis: Data of the AIR Registry registry. Am. Coll. Rheumatol. Ann. Sci. Meet. Abstract 1641 (2011).
35. Hochberg MC, Westhovens R, Aranda R et al. Long-term safety of abatacept: Integrated analysis of clinical prog up to 7 years of treatment [abstract]. Arthritis Rheum. 62(Suppl. 10), S164-S165 (2010).
36. Simon TA, Askling J, Lacaille D et al. Infections requiring hospitalization in the abatacept clinical development program: An epidemiological assessment. Arthritis Res. Ther. 12(2), R67 (2010
37. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 50(3), 552-562 (2011
38. Genovese M, Sebba A, Rubbert-Roth A et al. Long-term safety of tocilizumab in rheumatoid arthritis clinical trials. Am. Coll. Rheumatol. Ann. Sci. Meet. Abstract 2217 (2011
39. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, Van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 13(5), R141 (2011
40. Koike T, Harigai M, Inokuma S et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: Interim analysis of 3881 patients. Ann. Rheum. Dis. 70(12), 2148-2151 (2011
41. Hoshi D, Nakajima A, Inoue E et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod. Rheumatol. 22(1), 122-127 (2011
42. Buch MH, Smolen JS, Betteridge N et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70(6), 909-920 (2011
43. Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor aon host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect. Immun. 69(3), 1847-1855 (2001
44. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J. Med. 345(15), 1098-1104 (2001
45. Gomez-Reino JJ, Carmona L, Valverde VR et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum. 48(8), 2122-2127 (2003
46. Wolfe F, Michaud K, Anderson J et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50(2), 372-379 (2004
47. Askling J. Increased long-term risk for tuberculosis following treatmentwith TNF-antagonists. The Swedish experience 1999-2006. Ann. Rheum. Dis. 66(Suppl. II), S162 (2007
48. Seong SS, Choi CB, Woo JH et al. Incidence of tuberculosis in Korean patients with rheumatoiarthritis (RA): Effects of RA itself and of tumor necrosis factor blockers. J. Rheumatol. 34(4), 706-711 (2007
49. Tubach F, Salmon D, Ravaud P et al. The risk of tuberculosis with anti-TNF is higher with monoclonal antibodies than with the soluble receptor. Results of the French 3-year prospective RATIO observatory Ann. Rheum. Dis. 67(Suppl. II), S52 (2008
50. Tam LS, Leung CC, Ying SK et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong-the role of TNF blockers in an area of high tuberculosis burden. Clin. Exp. Rheumatol. 28(5), 679-685 (2010
51. Gomez-Reino JJ, Carmona L, Angel Descalzo M et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 57(5), 756-761 (2007
52. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF Therapytherapy: Results results from the BSRBR. Ann. Rheum. Dis. 69(3), 522-528 (2010
53. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 31(6), 456-473 (2005
54. Winthrop KL, Yamashita S, Beekmann SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the Emerging Infections Network. Clin. Infect. Dis. 46(11), 1738-1740 (2008
55. Jung N, Owczarczyk K, Hellmann M et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatology 47(6), 932-933 (2008
56. Burr ML, Malaviya AP, Gaston JH, Carmichael AJ, Ostor AJ. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatology 47(5), 738-739 (2008
57. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67(11), 1516-1523 (2008
58. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann. Rheum. Dis. 69(1), 88-96 (2010
59. Genentech Inc.: ACTEMRA (tocilizumab) (2010
60. Furst DE, Keystone EC, Fleischmann R et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann. Rheum. Dis. 69(Suppl. 1), i2-i29 (2010
61. Smitten AL, Choi HK, Hochberg MC et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 57(8), 1431-1438 (2007
62. Strangfeld A, Listing J, Herzer P et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-aagents. JAMA 301(7), 737-744 (2009
63. Serac G, Tubach F, Mariette X of herpes zoster in patients receiving anti-TNF-ain the prospective French RATIO registry. J. Invest. Dermatol. 132(3), 726-729 (2012
64. Garcia-Doval I, Perez-Zafrilla B, Descalzo MA et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann. Rheum. Dis. 69(10), 1751-1755 (2010
65. Roux C, Breuil V, Albert C et al. Ophthalmic herpes zoster infection in patients with rheumatoid arthritis who were treated with tocilizumab. J. Rheumatol. 38(2), 399 (2011
66. Kubandova Z, Mathieu S, Pourtier C, Soubrier M. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody. Joint Bone Spine 77(6), 623-624 (2010
67. Nishimoto N, Hashimoto J, Miyasaka N et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66(9), 1162-1167 (2007
68. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 68(10), 1580-1584 (2009
69. Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 359(14), 1486-1500 (2008
70. Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-ainhibitors. Hepatol. Res. 42(4), 333-339 (2011
71. Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin. Infect. Dis. 47(5), E52-E56 (2008
72. Kasahara S, Ando K, Saito K et al. Lack of tumor necrosis factor ainduces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J. Virol. 77(4), 2469-2476 (2003
73. Wendling D, Auge B, Bettinger D et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondylothropathy. Ann. Rheum. Dis. 64(5), 788-789 (2005
74. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-ablockade: Case reports. Clin. Rheumatol. 27(8), 1069-1071 (2008
75. Charpin C, Guis S, Colson P et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: Results from a cohort of 21 patients. Arthritis Res. Ther. 11(6), R179 (2009
76. Verhelst X, Orlent H, Colle I, Geerts A, De Vos M, Van Vlierberghe H. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur. J. Gastroenterol. Hepatol. 22(4), 494-499 (2010
77. Carroll MB, Forgione MA. Use of tumor necrosis factor ainhibitors in hepatitis B surface antigen-positive patients: A literature review and potential mechanisms of action. Clin. Rheumatol. 29(9), 1021-1029 (2010
78. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann. Rheum. Dis. 69(7), 1352-1355 (2010
79. Robinson H, Walker-Bone K. Anti-TNF-atherapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology 48(4), 448-450 (2009
80. Tamori A, Koike T, Goto H et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: Evaluation of both HBsAg-positive and HBsAg-negative cohorts. J. Gastroenterol. 46(4), 556-564 (2011
81. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-atherapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45(10), 1294-1297 (2006
82. Urata Y, Uesato R, Tanaka D et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod. Rheumatol. 21(1), 16-23 (2011
83. Kim YJ, Bae SC, Sung YK et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-ablocker in the treatment of rheumatic diseases. J. Rheumatol. 37(2), 346-350 (2010
84. Caporali R, Bobbio-Pallavicini F, Atzeni F et al. Safety of tumor necrosis factor ablockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/ anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res. 62(6), 749-754 (2010
85. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67(2), 189-194 (2008
86. Carro MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin. Biol. Ther. 11(4), 533-544 (2011
87. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68(1), 105-112 (1975
88. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 27(4), 605-611 (2009
89. Pei SN, Chen CH, Lee CM et al. Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients. Ann. Hematol. 89(3), 255-262 (2010
90. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol. Int. 31(3), 403-404 (2011
91. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 47(12), 1838-1840 (2008
92. Tsuboi H, Tsujii A, Nampei A et al. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. Mod. Rheumatol. 21(6), 701-705 (2011
93. Saag KG, Teng GG, Patkar NM et al. American college of rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 59(6), 762-784 (2008
94. Winthrop KL, Calabrese LH. Let the fog be lifted: Screening for hepatitis B virus before biological therapy. Ann. Rheum. Dis. 70(10), 1701-1703 (2011
95. Vigano M, Degasperi E, Aghemo A, Lampertico P, Colombo M. Anti-TNF drugs in patients with hepatitis B or C virus infection: Safety and clinical management. Expert Opin. Biol. Ther. 12(2), 193-207 (2012
96. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: Assessment and preventive strategies. Ann. Rheum. Dis. 65(8), 983-989 (2006
97. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int. 29(Suppl. 1), S1-S8 (2009
98. Brunasso AM, Puntoni M, Gulia A, Massone C. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: A systematic review. Rheumatology 50(9), 1700-1711 (2011
99. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: Where do we stand? Ann. Rheum. Dis. 67(3), 283-287 (2008
100. Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: Efficacy and safety in the absence of steroids. Rheumatology 45(7), 842-846 (2006
101. De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: Increased experience and perspectives. Dig. Liver Dis. 39(Suppl. 1), S122-S128 (2007
102. Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101(10), 3827-3834 (2003
103. Nagashima T, Maruyama A, Kamata Y, Minota S. Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatol. Int. 32(7), 2231-2232 (2011
104. Mahajan TD, Hooker R, Maher L, Brown G, Reimold A. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. J. Clin. Rheumatol. 16(7), 332-334 (2010
105. Ferri C, Govoni M, Calabrese L. The A, B, Cs of viral hepatitis in the biologic era. Curr. Opin. Rheumatol. 22(4), 443-450 (2010
106. Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Joint Bone Spine 79(4), 351-355 (2012
107. Nurmohamed MT. Newer biological agents in the treatment of rheumatoid arthritis: Do the benefits outweigh the risks? Drugs 69(15), 2035-2043 (2009
108. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N. Engl. J. Med. 350(21), 2167-2179 (2004
109. Sibilia J, Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Reumatol. 25(5 Suppl. 46), S46-S56 (2007
110. Tubach F, Mariette X, Ravaud P et al. The risk of Legionella pneumophila infection in patients treated with anti-TNF, results of the French 3-year prospective RATIO observatory. Ann. Rheum. Dis. 69(Suppl. 3), Abstract SAT0113 (2010
111. Lee JH, Slifman NR, Gershon SK et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor aantagonists infliximab and etanercept. Arthritis Rheum. 46(10), 2565-2570 (2002
112. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor a-neutralizing agents. Arthritis Rheum. 48(2), 319-324 (2003
113. Vallet H, Houitte R, Azria A, Mariette X. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis. J. Rheumatol. 38(5), 965-966 (2011
114. Balkwill F. TNF-ain promotion and progression of cancer. Cancer Metastasis Rev. 25(3), 409-416 (2006
115. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res. Ther. 10(2), R45 (2008
116. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: Meta and exposure-adjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 68(7), 1136-1145 (2009
117. Mariette X, Tubach F, Bagheri H et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 69(2), 400-408 (2010
118. Askling J, van Vollenhoven RF, Granath F et al. Cancer risk in patients with reumatoid arthritis treated with anti-tumor necrosis factor atherapies: Does the risk change with the time since start of treatment? Arthritis Rheum. 60(11), 3180-3189 (2009
119. Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register. Ann. Rheum. Dis. 68(5), 648-653 (2009
120. Askling J. Anti-TNF therapy and risk of skin cancer, data from the Swedish ARTIS registry 1998-2006 (abstract). Ann. Rheum. Dis. 68(Suppl. 3), S423 (2009) (Abstract
121. Wolfe F, Michaud K. Biologic treatment of rheumatod arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum. 56(9), 2886-2895 (2007
122. Amari W, Zeringue AL, Mcdonald JR, Caplan L, Eisen SA, Ranganathan P. Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis. Rheumatology 50(8), 1431-1439 (2011
123. Watson KD, Dixon WG, Hyrich KL, Lunt M, Symmons DP, Silman AJ. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): Results from the BSR biologics register (abstract). Ann. Rheum. Dis. 65(Suppl. 2), S512 (2006) (Abstract
124. Mercer LK, Green AC, Galloway JB et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 71(6), 869-874 (2012
125. Strangfeld A, Hierse F, Rau R et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res. Ther. 12(1), R5 (2010
126. Greenberg J, Strand V, Keystone E et al. TNF inhibitors (TNF-I) amd risk of malignancy in 8,072 followed over 15,495 patient years (abstract 282). Presented at: American College of Rheumatology 71st Annual Meeting. MA, USA, 6-11 November 2007 (Abstract 282
127. Abásolo L, Carmona L, Gómez-Reino JJ. Is the exposure to TNF antagonists a risk factor for cancer in rheumatoid arthritis? (abstract 1266). Am. Coll. Rheumatol. Ann. Sci. Meet. Abstract 1266 (2008
128. Mariette X, Matucci-Cerinic M, Pavelka K et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann. Rheum. Dis. 70(11), 1895-1904 (2011
129. Dixon WG, Watson KD, Lunt M et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results results from the British Society for rheumatology biologics register. Arthritis Care Res. 62(6), 755-763 (2010
130. Ding T, Ledingham J, Luqmani R et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 49(11), 2217-2219 (2010
131. van Vollenhoven RF, Smolen JS, Schiff M et al. Safety update on certolizumab apatients with active rheumatoid arthritis (abstract). Arthritis Rheum. 60(Suppl. 10), S1699 (2009
132. Kay J, Smolen J, Emery P et al. Pooled safety data from golimumab randomized, controlled trials in patients with rheumatoid arthiatic arthritis, and ankylosing spondylitis (abstract). Int. J. Rheum. Dis. 13(Suppl. 1), S85-S86 (2010) (Abstract
133. Spina M, Jaeger U, Sparano JA et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 Phase 2 trials. Blood 105(5), 1891-1897 (2005
134. Zeltser R, Valle L, Tanck C, Holyst MM, Ritchlin C, Gaspari AA. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated wercept: A recombinant tumor necrosis factor areceptor: Fc fusion protein. Arch. Dermatol. 137(7), 893-899 (2001
135. Paltiel M, Gober LM, Deng A et al. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch. Dermatol. 144(9), 1190-1194 (2008
136. Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 36(1), 3-10 (2005
137. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: Assessment and clinical relevance. Curr. Opin. Rheumatol. 21(3), 211-215 (2009
138. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: A systematic review and metaanalysis. J. Rheumatol. 33(12), 2398-2408 (2006
139. Lamour S, Bracher M, Nesbitt A. The PEG component of certolizumab pegol inhibits degranulation by stimulated mast clls [abstract]. Arthritis Rheum. 60(Suppl. 10), S44 (2009
140. Edwards J, Szczepanski L, Szechinski J. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004
141. Picchianti Diamanti A, Germano V, Bizzi E et al. Interstitial lung disease in rheumatoid arthritis in the era of biologics. Pulmon. Med. (2011
142. Ostör AJ, Chilvers ER, Somerville MF et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J. Rheumatol. 33(3), 622-628 (2006
143. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand. J. Rheumatol. 36(3), 172-178 (2007
144. Takeuchi T, Tatsuki Y, Nogami Y et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann. Rheum. Dis. 67(2), 189-194 (2008
145. Koike T, Harigai M, Ishiguro N et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: Postmarketing surveillance report of the first 3,000 patients. Mod. Rheumatol. doi:10.1007/s10165-011- 0541-5 (2011) (Epub ahead of print
146. Dixon WG, Hyrich KL, Watson KD, Lunt M, Consortium BC, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 69(6), 1086-1091 (2010
147. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJK. Non-infectious pulonary complications of newer biological agents for rheumatic diseases-a systematic literature review. Rheumatology 50(12), 2297-2305 (2011
148. Charles C, Clements P, Furst DE. Systemic sclerosis: Hypothesis-driven treatment strategies. Lancet 367(9523), 1683-1691 (2006
149. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am. J. Hematol. 82(10), 916-919 (2007
150. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology 48(4), 447-448 (2009
151. Dass S, Atzeni F, Vital E et al. Safety of rituximab in patients with rheumatoid arthritis and concomitant lung disease (abstract). Ann. Rheum. Dis. 70(Suppl. 3), S71 (2011
152. Matteson EL, Dellaripa PF, Ryu JH, Crowson CS, Hartman TE, Bongartz T. Open-label, pilot study of the safety and clinical effects of rituximab patients
153. Reynolds J, Toescu V, Yee C, Prabu A, Situnayake D, Gordon C. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 18(1), 67-73 (2009
154. Mcgonagle D, Tan AL, Madden J et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 47(4), 552-553 (2008
155. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: Lessons from failed and interrupted treatment trials. BioDrugs 16(3), 183-200 (2002
156. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-a-blocker therapy. Arch. Neurol. 66(4), 490497 (2009
157. Cminero A, Comabella M, Montalb X. Tumor necrosis factor a(TNF-a), anti-TNF-aand demyelination revisited: An ongoing story. J. Neuroimmunol. 234(1-2), 1-6 (2011
158. Furst DE, Keystone EC, Braun J et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann. Rheum. Dis. 70(Suppl. 1), i2-i36 (2011
159. Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-tumor necrosis factor atherapy for inflammatory arthritides. Arthritis Rheum. 44(12), 2862-2869 (2001
160. Fernández-Espartero MC, Pérez-Zafrilla B, Roselló R et al. Demyelinating diseases, optic nd multiple sclerosis in rheumatic diseases treated with anti-TNF therapy. Ann. Rheum. Dis. 68(Suppl. 3), S83 (2009
161. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann. Rheum. Dis. 69(9), 1691-1693 (2010
162. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure. Circulation 107(25), 3133-3140 (2003
163. Mann DL, McMurray JJV, Packer M et al. Targeted anticytokine therapy in patients with chronic heart failure. Circulation 109(13), 1594-1602 (2004
164. Westlake SL, Colebatch AN, Baird J et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: A systematic literature review. Rheumatology 50(3), 518-531 (2011
165. Setoguchi S, Schneeweiss S, Avorn J et al. Tumor necrosis factor-aantagonist use and heart failure in elderly patients with rheumatoid arthritis. Am. Heart J. 156(2), 336-341 (2008
166. Wolfe F, Mihaud K. Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. 116(5), 305-311 (2004
167. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology 44(5) 677-680 (2005
168. Hamid T, Gu Y, Ortines RV et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure. Circulation 119(10), 1386-1397 (2009
169. Danila MI, Patkar NM, Curtis JR, Saag KG, Teng GG. Biologics and heart failure in rheumatoid arthritis: Are we any wiser? Curr. Opin. Rheumatol. 20(3), 327-333 (2008
170. Nikolaidis LA. When cancer and heart failure cross paths: A case report of severe cardiorenal compromise associated with the anti-CD20 monoclonal antibody rituximab in a patient with dilated cardiomyopathy. Congest. Heart Fail. 7(4), 223-227 (2001
171. Peters MJ, Symmons DP, Mccarey D et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69(2), 325-331 (2010
172. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: A challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 68(4), 460-469 (2009
173. Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-analysis of six initial trials and five long-term extensions. Mod. Rheumatol. 20(3), 222-232 (2010
174. Curtis JR, Xie F, Chen L et al. The incidence of gastrointestinal perforations among rheumatoid arthritis patients. Arthritis Rheum. 63(2), 346-351 (2011
175. Smolen JS, Landewé R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis. 69(6), 964-975 (2010
176. Mancini S, Amorotti E, Vecchio S, Ponz De Leon M, Roncucci L. Infliximab-related hepatitis: Discussion of a case and review of the literature. Intern. Emerg. Med. 5(3), 193-200 (2010
177. Sokolove J, Strand V, Greenberg JD et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann. Rheum. Dis. 69(9), 1612-1617 (2010